NCT07299474 Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures
| NCT ID | NCT07299474 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Inferior Turbinate Hypertrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 184 participants |
| Start Date | 2025-12 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 184 participants in total. It began in 2025-12 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The main questions it aims to answer are: * Does lavender aromatherapy help reduce anxiety and/or pain, and improve patient comfort during awake otolaryngologic procedures in the clinic? * Do patients subjectively find aromatherapy relaxing and/or beneficial during the procedure? Researchers will compare lavender aromatherapy to placebo (an odorless liquid) to see if lavender aromatherapy helps improve patient comfort during their awake procedure Participants will: * Have their scheduled procedure performed with lavender aromatherapy or placebo during the duration of the procedure * Take a short, less than 1 minute questionnaire both before and after the procedure, describing their levels of anxiety, pain and subjective impressions of the aromatherapy
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years old undergoing awake otolaryngologic procedures in the outpatient clinic * Able to provide informed consent Exclusion Criteria: * Hypersensitivity to fragrances * Taking systemic NSAIDs or other systemic pain-relieving medications within 48 hours * Taking anxiolytics, hypnotics, sedating antihistamines, antidepressants on regular basis within 4 weeks * Pregnant or breastfeeding * Participation in another clinical research study within the prior 30 days
Contact & Investigator
Ankona Ghosh, MD
PRINCIPAL INVESTIGATOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT07299474 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inferior Turbinate Hypertrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07299474 currently recruiting?
Yes, NCT07299474 is actively recruiting participants. Contact the research team at dhruv.kothari@cshs.org for enrollment information.
Where is the NCT07299474 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07299474 clinical trial?
NCT07299474 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Ankona Ghosh, MD at Cedars-Sinai Medical Center. The trial plans to enroll 184 participants.